皮肤透光静脉血管整形用于神经性胸部出口综合征
Jenny N Wang1, Meghan He2, Snehal Bindra3
1University of California Irvine School of Medicine, CA.
Annals of vascular surgery
|May 8, 2025
概括
皮肤透光静脉血管造形术 (PTVA) 为神经性胸部外出综合征 (nTOS) 提供了一种安全有效的治疗方法,减少了许多患者开放手术的需要. 这种内血管干预应被认为是手术减压前的主要治疗选择.
科学领域:
- 血管外科 血管外科
- 干预性放射学 干预性放射学
- 神经外科 神经外科
背景情况:
- 神经性胸部外出综合征 (nTOS) 是一个复杂的临床挑战.
- 物理治疗的保守管理是NTOS的首选治疗方法.
- 一部分nTOS患者对保守治疗没有反应,需要进一步干预.
研究的目的:
- 评估通过皮肤进行透光静脉血管造形术 (PTVA) 在治疗nTOS时的疗效和安全性.
- 评估PTVA对缓解症状的影响以及后续干预的必要性.
- 确定PTVA是否可以作为NTOS的开放性外科解压的替代方案.
主要方法:
- 从2010-2019年对1,194名nTOS患者的回顾性分析.
- 确定了307名失败于保守治疗的患者,并接受了诊断性静脉谱.
- 291名具有显著静脉狭窄的患者接受了PTVA治疗;随访时间平均为19个月.
主要成果:
- 在PTVA后,59%的患者报告了最初的症状改善.
- 49%的患者在PTVA后不需要进一步治疗.
- 69%的PTVA治疗患者成功避免了开放式手术,并发症率低 (0.3%).
结论:
- PTVA是一种安全有效的治疗方式,用于静脉狭窄症的nTOS患者.
- PTVA显著降低了开放式手术减压的要求.
- 在对nTOS进行手术之前,应考虑使用PTVA进行内血管治疗.
更多相关视频
05:44Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
526
05:17Author Spotlight: Scope of LE-ULBD as a Safe, Effective, and Minimally Invasive Approach to Treat Lumbar Spinal Stenosis
Published on: February 9, 2024
443
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
101
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
101
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
87
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
87